Please login to the form below

Not currently logged in
Email:
Password:

FDA clears Advair follow up Breo for asthma

But respiratory drug given the thumbs up for adults only

GSK GlaxoSmithKline house 

GlaxoSmithKline (GSK) and Theravance have won US FDA approval for respiratory drug Breo for asthma in adults, but not in children.

The decision to limit use of the Breo (fluticasone furoate/vilanterol) to patients aged 18 years and older was expected after an FDA advisory committee voted in March not to recommend approval in younger patients. 

The reluctance stems from longstanding caution at the FDA about the safety of long-acting beta agonists and inhaled corticosteroids, so the approval of the combination in adults - after a five-year hiatus - is something of a step forward even with the exclusion of children from the label.  

The FDA has already asked GSK and Theravance to carry out additional studies to show its safety in the paediatric setting. Analysts have suggested that adults remain the largest market segment however, adding that approval in asthma should help Breo top the $1bn threshold by 2020.

Breo - a follow-up to GSK's big-selling Advair (fluticasone propionate/salmeterol) brand - has been approved as a once-daily therapy and is the second asthma drug to be approved in the US from GSK in the last year after Arnuity (fluticasone furoate) got the nod last August.

The green light in asthma comes two years after Breo was approved by the US regulator as a treatment for chronic obstructive pulmonary disease (COPD)

Breo and other new drugs such as Anoro (umeclidinium bromide/vilanterol) have been positioned as successors to Advair, which saw sales slip 15% to a little over £4.2bn ($6.35bn) last year  - although increasing competition and downward pricing pressure in the respiratory market has pegged back the growth of its respiratory franchise.

Analysts predict that GSK's new combination asthma and COPD drugs and those from competitors such as Novartis and Boehringer Ingelheim are more likely to sell in the $1bn-$2bn range, a step down from Advair's performance at peak.

With that in mind, GSK and Theravance have started developing a triple therapy - based on fluticasone, umeclidinium and vilanterol delivered via a single device - that they hope will show sufficient improvement over dual therapy rivals to set a new standard respiratory therapy.

Article by
Phil Taylor

5th May 2015

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....